Showing results (1461-1470 of 1,485) with videos related to

Sort By:
Pageof 149
Clinical and Molecular Hepatology|April 19, 2024
Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapyPei-Chien Tsai, Chung-Feng Huang, Ming-Lun Yeh, et al.
Scientific Reports|December 7, 2021
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in TaiwanChung-Feng Huang, Hsing-Tao Kuo, Te-Sheng Chang, et al.
Journal of Viral Hepatitis|September 13, 2025
Impact of Concurrent Steatotic Liver Disease and Chronic Hepatitis B on Treatment Response to Nucleos(t)ide AnalogsAngela Chau, Jie Li, Dae Won Jun, et al.
The Lancet. Gastroenterology & Hepatology|May 23, 2025
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trialYinghong Shi, Guohong Han, Jian Zhou, et al.
Hepatology International|January 21, 2024
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from TaiwanMing-Lung Yu, Chi-Ming Tai, Lein-Ray Mo, et al.
The Kaohsiung Journal of Medical Sciences|June 20, 2025
Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in TaiwanSzu-Jen Wang, Te-Sheng Chang, Ching-Chu Lo, et al.
Hepatology International|March 27, 2023
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registryTe-Sheng Chang, Chung-Feng Huang, Hsing-Tao Kuo, et al.
The Kaohsiung Journal of Medical Sciences|January 20, 2025
Real-world efficacy and safety of universal 8-week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre-end-stage renal disease: Insights from a nationwide hepatisis C virus registry in TaiwanSzu-Jen Wang, Chung-Feng Huang, Te-Sheng Chang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|August 21, 2024
Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients -a nationwide Taiwan HCV registryTyng-Yuan Jang, Chung-Feng Huang, Te-Sheng Chang, et al.
Infectious Diseases and Therapy|April 28, 2024
Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in TaiwanChun-Chi Yang, Chung-Feng Huang, Te-Sheng Chang, et al.
Pageof 149